Article

Population-based study of wake-up strokes.

University of Cincinnati, Department of Neurology, Cincinnati, OH 45219, USA.
Neurology (Impact Factor: 8.3). 05/2011; 76(19):1662-7. DOI: 10.1212/WNL.0b013e318219fb30
Source: PubMed

ABSTRACT Previous studies have estimated that wake-up strokes comprise 8%to 28% of all ischemic strokes, but these studies were either small or not population-based. We sought to establish the proportion and event rate of wake-up strokes in a large population-based study and to compare patients who awoke with stroke symptoms with those who were awake at time of onset.
First-time and recurrent ischemic strokes among residents of the Greater Cincinnati/Northern Kentucky region (population 1.3 million) in 2005 were identified using International Classification of Diseases-9 codes 430-436 and verified via study physician review. Ischemic strokes in patients aged 18 years and older presenting to an emergency department were included. Baseline characteristics were ascertained, along with discharge modified Rankin Scale scores and 90-day mortality.
We identified 1,854 ischemic strokes presenting to an emergency department, of which 273 (14.3%) were wake-up strokes. There were no differences between wake-up strokes and all other strokes with regard to clinical features or outcomes except for minor differences in age and baseline retrospective NIH Stroke Scale score. The adjusted wake-up stroke event rate was 26.0/100,000. Of the wake-up strokes, at least 98 (35.9%) would have been eligible for thrombolysis if arrival time were not a factor.
Within our population, approximately 14% of ischemic strokes presenting to an emergency department were wake-up strokes. Wake-up strokes cannot be distinguished from other strokes by clinical features or outcome. We estimate that approximately 58,000 patients with wake-up strokes presented to an emergency department in the United States in 2005.

0 Bookmarks
 · 
148 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intravenous thrombolysis (IVT) with alteplase remains the standard treatment for acute ischemic stroke. Although IVT can be started up to 4.5 hours after symptoms’ onset, it is all the more effective and safe when started early. It allows a 10% absolute reduction in the risk of handicap or death at 3 months, despite a 2–7% risk of symptomatic intracranial hemorrhage. Current research efforts involve firstly trying to treat a larger proportion of patients by overcoming some of the contraindications to IVT and secondly assessing combined or alternative treatments to achieve a higher early recanalization rate.
    11/2014; DOI:10.1016/j.diii.2014.10.002
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients, who wake up with an ischemic stroke, account for a large number of the total stroke population, due to circadian morning predominance of stroke. Currently, this subset of patients is excluded from revascularization-therapy since no exact time of onset is known. A large group of these patients might be eligible for therapy. In this review, we assessed the current literature about the hypothesis that wake-up-strokes occur just prior on awakening and if this subgroup differs in characteristics compared to the overall stroke population. We looked at the safety and efficacy of thrombolysis and interventional techniques in the group of patients with unknown stroke-onset. We performed a meta-analysis of the diagnostic accuracy of the diffusion-FLAIR mismatch in identifying stroke within 3 and 4.5 h. The different imaging-selection criteria that can be used to treat these patients are discussed. Additional research on imaging findings associated with recent stroke and penumbral imaging will eventually lead to a shift from a rigid time-frame based therapy to a tissue-based individualized treatment approach.
    Frontiers in Neurology 08/2014; 5:153. DOI:10.3389/fneur.2014.00153
    This article is viewable in ResearchGate's enriched format
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: La thrombolyse intraveineuse (TIV) par alteplase reste à ce jour le traitement de référence de l’infarctus cérébral à la phase aiguë. Bien qu’elle puisse être débutée jusqu’à 4 h 30 après le début des symptômes, elle est d’autant plus efficace et sûre qu’elle est initiée précocement. Elle permet une réduction absolue de l’ordre de 10 % du risque de handicap ou de décès à 3 mois, au prix d’un risque de transformation hémorragique cérébrale symptomatique de 2 % à 7 %. Les principaux efforts de recherche actuels consistent d’une part à essayer de traiter une plus grande proportion de patients en repoussant certaines contre-indications de la TIV, et d’autre part à évaluer des traitements combinés ou alternatifs, en vue d’obtenir un taux de recanalisation précoce plus important.
    11/2014; DOI:10.1016/j.jradio.2014.09.004

Full-text (2 Sources)

Download
24 Downloads
Available from
May 23, 2014